Navigation Links
MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Date:9/24/2007

GAITHERSBURG, Md., Sept. 24 /PRNewswire/ -- MedImmune, Inc. announced today that it has licensed its proprietary reverse genetics intellectual property to GlaxoSmithKline to support the development and construction of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only with segments of the virus's genome.

"MedImmune is pleased to enter into a fourth agreement to license our reverse genetics technology to manufacturers," said Jonathan Klein-Evans, J.D., MedImmune's vice president, intellectual property. "Making this important technology available to the vaccine development team at GlaxoSmithKline and their peers at other companies may have a significant positive impact on the manufacturing of influenza vaccines due to the efficiency and reliability of the process."

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates because it allows them to avoid working directly with the infectious, circulating pandemic strains. As the owner or exclusive licensee of key patent estates for use of the reverse genetics technology in human influenza vaccines, MedImmune remains committed to making sure that the technology is accessible to government institutions and industry manufacturers. As such, the company has offered other influenza vaccine manufacturers non-exclusive licenses to this intellectual prope
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. US Government Licenses New Hypertension Drug
2. Panacea Biotec In-Licenses FMD Vaccine
3. Thailand Goes Ahead With Licenses for Generic Drugs
4. Swedish Biotech Licenses HIV Drug to China for Development
5. More Foreign Trained Doctors Receive Licenses
6. FDA Licenses First US Vaccine Against Avian Flu
7. Thailand Will Not Issue Compulsory Licenses for Patented Drugs
8. Vitamin C reverses pre eclampsia
9. Creams may not reverse aging
10. Researchers reversed the process of memory loss
11. Faster way of producing Bird flu vaccine using Reverse Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
... research proves drug-coated stents effectively co...the real world.// A new study from researchers in...al trials of drug-coated stents represented a very...his new study takes a closer look at the effects o...
...ew study shows providing behavior and development ...ves the quality of pediatric health care and paren...ns Bloomberg School of Public Health followed near...s designed to bridge the gap between families and ...
...ew study shows that the risk of depression increas...own individuals who are insulin-resistant may have... prone to depression and even suicide. Research...y associated with depression and that their result...
...ew study reveals that a tonsillectomy procedure us...ay be the key to reducing pain during recovery. //...method, a special scalpel heats tissue as it goes ...procedure. The microdissection needle technique us...
Other Medicine News:Health News:Stronger Backing for Drug-Coated Stents 2
(Date:10/6/2008)...ildren, parents discussing clinical ...PRNewswire-USNewswire/ -- From asthma and cancer,t...lives and improves their,health and well-being. A ...h (NIH), "Children and Clinical Studies", (http://...fers parents and health,care providers an insider,...
(Date:10/6/2008)...DE Therapy is More Likely to Induce Steroid-Free...ard Immunomodulator, Azathiopr...resented for the first time,from the Phase 3b Stud...modulators and Biologic Therapy (SONIC) may provid...ts with moderate to severe Crohn,s disease.,Accord...
(Date:10/6/2008)...ed for 9:00 AM ET Today -, SEATTLE, Oct. 6 /PRNew...DNDN) announced today that it has completed the pl... double-blind, placebo-controlled IMPACT,(IMmunoth...known as D9902B),clinical trial designed to assess...tive cellular immunotherapy PROVENGE(R) (sipuleuce...
(Date:10/6/2008)...ompany,s Bioabsorbable Stent - Also,Slated for Pre...wire/ -- Data from multiple clinical trials of,the...ous Bio-engineered R,stent, will be presented next...tics symposium, TCT 2008, in Washington, D.C., Ro...cal Center in,Amsterdam will provide a Genous clin...
Breaking Medicine Technology:Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 1Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 2Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2082 4Medicares Drug Program Enrollment Up Costs Down 10702 1Medicares Drug Program Enrollment Up Costs Down 10702 2Medicares Drug Program Enrollment Up Costs Down 10702 3Genghis Grill Offers Recipes Featuring Heart Healthy Dining Options 10697 1Genghis Grill Offers Recipes Featuring Heart Healthy Dining Options 10697 2Britney Spears 3A Lets Talk About All of Us 10692 1Britney Spears 3A Lets Talk About All of Us 10692 2
...esponse, Health Organizations Unite to Help Educat...e Risk of Other Serious,Health Problems, SEATTLE, ...,report looking at the prevalence and cost of type...three out of five people,(57.9 percent) with type ...health problems commonly associated with the disea...
... YORK, April 10, 2007 /PRNewswire-FirstCall/ -- Im...b Company today,announced that a Phase III study o...therapy) in patients with locally advanced,unresec... its,primary endpoint of improving overall surviva...OG), a cancer,center network sponsored by the Nati...
Other Medicine Technology:First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: